16 assets in Breast-Ovarian Cancer, Familial, Susceptibility To, 1

Therapeutic assets addressing Breast-Ovarian Cancer, Familial, Susceptibility To, 1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Breast-Ovarian Cancer, Familial, Susceptibility To, 1	University of California, San Francisco	P2	B (58)
Niraparib Breast-Ovarian Cancer, Familial, Susceptibility To, 1	University of California, San Francisco	P2	B (58)
Olaparib Breast-Ovarian Cancer, Familial, Susceptibility To, 1	GBG Forschungs GmbH	P2	B (58)
Denosumab Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Alliance for Clinical Trials in Oncology	P3	B (57)
Carboplatin Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Okayama University	P2	CCC (53)
Durvalumab Breast-Ovarian Cancer, Familial, Susceptibility To, 1	European Organisation for Research and Treatment of Cancer - EORTC	P2	CCC (53)
Elacestrant Breast-Ovarian Cancer, Familial, Susceptibility To, 1	GBG Forschungs GmbH	P2	CCC (53)
Pembrolizumab Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Okayama University	P2	CCC (53)
Ace-86225106 Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Acerand Therapeutics (Shanghai) Limited	P1/2	CC (45)
Etx-19477 Breast-Ovarian Cancer, Familial, Susceptibility To, 1	858 Therapeutics, Inc.	P1/2	CC (45)
tng348 Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Tango Therapeutics, Inc.	P1/2	CC (45)
Aquocobalamin Breast-Ovarian Cancer, Familial, Susceptibility To, 1	General Oncology, Inc.	P1	CC (41)
Camustine Breast-Ovarian Cancer, Familial, Susceptibility To, 1	General Oncology, Inc.	P1	CC (41)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer Breast-Ovarian Cancer, Familial, Susceptibility To, 1	Dana-Farber Cancer Institute	P1	CC (41)
Melphalan Breast-Ovarian Cancer, Familial, Susceptibility To, 1	General Oncology, Inc.	P1	CC (41)